WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 315265
CAS#: 638-94-8
Description: Desonide is the generic name of a low potency topical corticosteroid that has been available since the 1970s. It is primarily used to treat atopic dermatitis (eczema), seborrheic dermatitis, psoriasis and contact dermatitis in both adults and children and has a fairly good safety profile and is available as a cream, ointment, lotion, and, since September 19, 2006, as a foam under the tradename Verdeso Foam.
MedKoo Cat#: 315265
Name: Desonide
CAS#: 638-94-8
Chemical Formula: C24H32O6
Exact Mass: 416.21989
Molecular Weight: 416.51
Elemental Analysis: C, 69.21; H, 7.74; O, 23.05
Synonym: (1116)1121dihydroxy1617(1methylethylidene)bis(oxy)pregna14diene320dione.
IUPAC/Chemical Name: (6aR,7S,8aS,8bS,11aR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
InChi Key: WBGKWQHBNHJJPZ-QHDHGWJCSA-N
InChi Code: InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15?,16?,17-,19+,20?,22-,23-,24+/m0/s1
SMILES Code: O=C(C=C[C@@]12C)C=C1CCC(C2[C@@H](O)C[C@@]34C)C3C[C@]5([H])[C@@]4(C(CO)=O)OC(C)(C)O5
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 416.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Yentzer BA, Camacho FT, Young T, Fountain JM, Clark AR, Feldman SR. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. J Drugs Dermatol. 2010 Apr;9(4):324-9. PubMed PMID: 20514788.
2: Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009 Nov-Dec;27(6 Suppl):S48-53. PubMed PMID: 19878781.
3: Kircik LH. Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05%. J Clin Aesthet Dermatol. 2009 Feb;2(2):32-6. PubMed PMID: 20967179; PubMed Central PMCID: PMC2958180.
4: Hebert AA; Desonide Foam Phase III Clinical Study Group. Desonide foam 0.05%: safety in children as young as 3 months. J Am Acad Dermatol. 2008 Aug;59(2):334-40. PubMed PMID: 18638631.
5: Kahanek N, Gelbard C, Hebert A. Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs. 2008 Jul;17(7):1097-104. Review. PubMed PMID: 18549345.
6: Parish D, Scheinfeld N. Desonide foam: a review. Drugs Today (Barc). 2008 Jan;44(1):55-62. Review. PubMed PMID: 18301804.
7: Scheinfeld NS, Parish DH. Desonide gel. Skinmed. 2007 Sep-Oct;6(5):241. PubMed PMID: 17786103.
8: Bhankharia DA, Sanjana PH. Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study. Indian J Dermatol Venereol Leprol. 2004 Sep-Oct;70(5):288-91. PubMed PMID: 17642640.
9: Eichenfield LF, Basu S, Calvarese B, Trancik RJ. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol. 2007 May-Jun;24(3):289-95. PubMed PMID: 17542883.
10: Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ; Desonide Hydrogel Study Group. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol. 2007 Feb;6(2):175-81. PubMed PMID: 17373176.
